Oligodendroglioma poses a biological conundrum for malignant adult human gliomas: it is a tumor type that is universally incurable for patients, and yet, only a few of the human tumors have been established as cell populations in vitro or as intracranial xenografts in vivo. Their survival, thus, may emerge only within a specific environmental context. To determine the fate of human oligodendroglioma in an experimental model, we studied the development of an anaplastic tumor after intracranial implantation into enhanced green fluorescent protein (eGFP) positive NOD/SCID mice. Remarkably after nearly nine months, the tumor not only engrafted, but it also retained classic histological and genetic features of human oligodendroglioma, in particular cells with a clear cytoplasm, showing an infiltrative growth pattern, and harboring mutations of IDH1 (R132H) and of the tumor suppressor genes, FUBP1 and CIC. The xenografts were highly invasive, exhibiting a distinct migration and growth pattern around neurons, especially in the hippocampus, and following white matter tracts of the corpus callosum with tumor cells accumulating around established vasculature. Although tumors exhibited a high growth fraction in vivo, neither cells from the original patient tumor nor the xenograft exhibited significant growth in vitro over a six-month period. This glioma xenograft is the first to display a pure oligodendroglioma histology and expression of R132H. The unexpected property, that the cells fail to grow in vitro even after passage through the mouse, allows us to uniquely investigate the relationship of this oligodendroglioma with the in vivo microenvironment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602110PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059773PLOS

Publication Analysis

Top Keywords

fubp1 cic
8
human oligodendroglioma
8
growth pattern
8
oligodendroglioma
6
tumor
6
human
5
novel diffusely
4
diffusely infiltrative
4
infiltrative xenograft
4
xenograft model
4

Similar Publications

Multiomics analysis of homologous recombination deficiency across cancer types.

Biomol Biomed

December 2024

Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China; Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

There remains ongoing debate regarding the association of homologous recombination deficiency (HRD) with patient survival across various malignancies, highlighting the need for a comprehensive understanding of HRD's role in different cancer types. Based on data from databases, we conducted a multivariable omics analysis on HRD in 33 cancer types, focusing mainly on 23 cancers in which HRD was significantly associated with patient overall survival (OS) rates. This analysis included the mechanisms related to patient prognosis, gene expression, gene mutation, and signaling pathways.

View Article and Find Full Text PDF
Article Synopsis
  • Oligodendrogliomas, known for specific genetic mutations (IDH1/2) and chromosome deletions (1p/19q), were analyzed in a study to understand the clinical significance of additional genomic alterations like CIC, FUBP1, and TERTp using clinically standardized NGS panels.
  • The analysis included 277 patients diagnosed between 2005 and 2021, revealing that among the 95 patients with NGS reports, CIC, FUBP1, and TERTp were the most commonly altered genes.
  • While these genetic alterations were frequent, the study found that most did not significantly impact progression-free or overall survival, except for a noted reduction in progression-free survival associated with CIC alterations in specific
View Article and Find Full Text PDF

Genomic alterations of oligodendrogliomas at distant recurrence.

Cancer Med

August 2023

Department of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.

Background: Oligodendroglioma is known for its relatively better prognosis and responsiveness to radiotherapy and chemotherapy. However, little is known about the evolution of genetic changes as oligodendroglioma progresses.

Methods: In this study, we evaluated gene evolution invivo during tumor progression based on deep whole-genome sequencing data (ctDNA).

View Article and Find Full Text PDF

This study aimed to find any ambiguous genetic outlier for "oligodendroglioma, IDH-mutant and 1p/19q-codeleted (O_IDH_mut)" and "astrocytoma, IDH-mutant (A_IDH_mut)" and to redefine the genetic landscape and prognostic factors of IDH-mutant gliomas. Next-generation sequencing (NGS) using a brain tumor-targeted gene panel, methylation profiles, and clinicopathological features were analyzed for O_IDH_mut (n = 74) in 70 patients and for A_IDH_mut (n = 95) in 90 patients. 97.

View Article and Find Full Text PDF

Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumors.

Front Oncol

March 2023

Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: The 5th edition of the World Health Organization (WHO) classification of central nervous system tumors incorporated specific molecular alterations into the categorization of gliomas. The major revision of the classification scheme effectuates significant changes in the diagnosis and management of glioma. This study aimed to depict the clinical, molecular, and prognostic characteristics of glioma and its subtypes according to the current WHO classification.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!